Show simple item record

dc.contributor.authorDenninger, Viola
dc.contributor.authorXu, Catherine K
dc.contributor.authorMeisl, Georg
dc.contributor.authorMorgunov, Alexey S
dc.contributor.authorFiedler, Sebastian
dc.contributor.authorIlsley, Alison
dc.contributor.authorEmmenegger, Marc
dc.contributor.authorMalik, Anisa Y
dc.contributor.authorPiziorska, Monika A
dc.contributor.authorSchneider, Matthias
dc.contributor.authorDevenish, Sean RA
dc.contributor.authorKosmoliaptsis, Vasilis
dc.contributor.authorAguzzi, Adriano
dc.contributor.authorFiegler, Heike
dc.contributor.authorKnowles, Tuomas
dc.date.accessioned2022-04-30T01:04:10Z
dc.date.available2022-04-30T01:04:10Z
dc.date.issued2022-04-08
dc.identifier.issn2373-8227
dc.identifier.other35352558
dc.identifier.otherPMC8982494
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/336648
dc.descriptionFunder: Universit?tsspital Z?rich
dc.descriptionFunder: Biotechnology and Biological Sciences Research Council
dc.descriptionFunder: NOMIS Stiftung
dc.descriptionFunder: Universit?t Z?rich
dc.description.abstractRecent efforts in understanding the course and severity of SARS-CoV-2 infections have highlighted both potentially beneficial and detrimental effects of cross-reactive antibodies derived from memory immunity. Specifically, due to a significant degree of sequence similarity between SARS-CoV-2 and other members of the coronavirus family, memory B-cells that emerged from previous infections with endemic human coronaviruses (HCoVs) could be reactivated upon encountering the newly emerged SARS-CoV-2, thus prompting the production of cross-reactive antibodies. Determining the affinity and concentration of these potentially cross-reactive antibodies to the new SARS-CoV-2 antigens is therefore particularly important when assessing both existing immunity against common HCoVs and adverse effects like antibody-dependent enhancement (ADE) in COVID-19. However, these two fundamental parameters cannot easily be disentangled by surface-based assays like enzyme-linked immunosorbent assays (ELISAs), which are routinely used to assess cross-reactivity. Here, we have used microfluidic antibody affinity profiling (MAAP) to quantitatively evaluate the humoral immune response in COVID-19 convalescent patients by determining both antibody affinity and concentration against spike antigens of SARS-CoV-2 directly in nine convalescent COVID-19 patient and three pre-pandemic sera that were seropositive for common HCoVs. All 12 sera contained low concentrations of high-affinity antibodies against spike antigens of HCoV-NL63 and HCoV-HKU1, indicative of past exposure to these pathogens, while the affinity against the SARS-CoV-2 spike protein was lower. These results suggest that cross-reactivity as a consequence of memory reactivation upon an acute SARS-CoV-2 infection may not be a significant factor in generating immunity against SARS-CoV-2.
dc.languageeng
dc.publisherAmerican Chemical Society (ACS)
dc.sourcenlmid: 101654580
dc.sourceessn: 2373-8227
dc.subjectAntibody affinity
dc.subjectcross-reactivity
dc.subjectMicrofluidics
dc.subjectAntibody Profiling
dc.subjectAntibody Concentration
dc.subjectSars-cov-2
dc.subjectHumans
dc.subjectAntibodies, Viral
dc.subjectAntibody Affinity
dc.subjectSpike Glycoprotein, Coronavirus
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.titleMicrofluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2.
dc.typeArticle
dc.date.updated2022-04-30T01:04:09Z
prism.endingPage799
prism.issueIdentifier4
prism.publicationNameACS Infect Dis
prism.startingPage790
prism.volume8
dc.identifier.doi10.17863/CAM.84069
rioxxterms.versionofrecord10.1021/acsinfecdis.1c00486
rioxxterms.versionVoR
dc.contributor.orcidDenninger, Viola [0000-0001-9770-8723]
dc.contributor.orcidXu, Catherine K [0000-0003-4726-636X]
dc.contributor.orcidMeisl, Georg [0000-0002-6562-7715]
dc.contributor.orcidFiedler, Sebastian [0000-0003-0953-4327]
dc.contributor.orcidSchneider, Matthias [0000-0002-1894-1859]
dc.contributor.orcidKosmoliaptsis, Vasilis [0000-0001-7298-1387]
dc.contributor.orcidKnowles, Tuomas [0000-0002-7879-0140]
dc.identifier.eissn2373-8227
pubs.funder-project-idNational Institute for Health Research (NIHR) (PD-2016-09-065)
pubs.funder-project-idEuropean Research Council (670958)
pubs.funder-project-idSchweizerische Akademie der Medizinischen Wissenschaften (2017DRI17)
cam.issuedOnline2022-03-30


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record